These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 18316582

  • 1. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma.
    Huszthy PC, Goplen D, Thorsen F, Immervoll H, Wang J, Gutermann A, Miletic H, Bjerkvig R.
    Clin Cancer Res; 2008 Mar 01; 14(5):1571-80. PubMed ID: 18316582
    [Abstract] [Full Text] [Related]

  • 2. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG.
    Cancer Res; 2001 Apr 01; 61(7):2983-95. PubMed ID: 11306477
    [Abstract] [Full Text] [Related]

  • 3. Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment.
    Huszthy PC, Immervoll H, Wang J, Goplen D, Miletic H, Eide GE, Bjerkvig R.
    Gene Ther; 2010 Feb 01; 17(2):202-16. PubMed ID: 19829315
    [Abstract] [Full Text] [Related]

  • 4. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, Gonen M, Ebright MI, Culliford A, Gusani NJ, Fong Y.
    Cancer Gene Ther; 2006 Mar 01; 13(3):326-34. PubMed ID: 16138120
    [Abstract] [Full Text] [Related]

  • 5. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
    Aghi M, Rabkin SD, Martuza RL.
    Cancer Res; 2007 Jan 15; 67(2):440-4. PubMed ID: 17234749
    [Abstract] [Full Text] [Related]

  • 6. Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment.
    Hoffmann D, Wildner O.
    Cancer Gene Ther; 2007 Jul 15; 14(7):627-39. PubMed ID: 17479104
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.
    Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR, Rubin SC, Albelda SM, Molnar-Kimber KL.
    Clin Cancer Res; 1999 Jun 15; 5(6):1523-37. PubMed ID: 10389942
    [Abstract] [Full Text] [Related]

  • 10. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G, Makrigiannakis A, Montas S, Kaiser LR, Toyozumi T, Benjamin I, Albelda SM, Rubin SC, Molnar-Kimber KL.
    Cancer Gene Ther; 2000 Feb 15; 7(2):275-83. PubMed ID: 10770637
    [Abstract] [Full Text] [Related]

  • 11. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
    Kambara H, Saeki Y, Chiocca EA.
    Cancer Res; 2005 Dec 15; 65(24):11255-8. PubMed ID: 16357128
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.
    Nakano K, Todo T, Chijiiwa K, Tanaka M.
    Mol Ther; 2001 Apr 15; 3(4):431-7. PubMed ID: 11319903
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D, Goshima F, Mori I, Tamada Y, Matsumoto Y, Nishiyama Y.
    J Dermatol Sci; 2008 Jun 15; 50(3):185-96. PubMed ID: 18226503
    [Abstract] [Full Text] [Related]

  • 16. G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro.
    Lee JH, Federoff HJ, Schoeniger LO.
    J Gastrointest Surg; 1999 Jun 15; 3(2):127-31; discussion 132-3. PubMed ID: 10457334
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
    Kim SH, Wong RJ, Kooby DA, Carew JF, Adusumilli PS, Patel SG, Shah JP, Fong Y.
    Eur J Cancer; 2005 Jan 15; 41(2):313-22. PubMed ID: 15661558
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.